Omitting Lymphadenectomy Reduces AEs, Does Not Lower DFS in Cervical Cancer
A recent study published in The New England Journal of Medicine has revealed that omitting lymphadenectomy in cervical cancer patients can significantly reduce adverse events (AEs) without compromising disease-free survival (DFS). The study, known as the PHENIX trial, compared the outcomes of patients who underwent sentinel-lymph node biopsy alone with those who received lymphadenectomy.
The 3-year DFS rate was notably higher in the biopsy-only group, at 96.9%, compared to 94.6% in the lymphadenectomy group. This finding challenges the traditional belief that lymphadenectomy is essential for optimal DFS in cervical cancer treatment. Interestingly, the study also found that lymphadenectomy resulted in higher rates of adverse events, including lymphocyst, lymphedema, hypoalbuminemia, paresthesia, and pain.
The authors of the study, led by Dr. Hua Tu from Sun Yat-sen University Cancer Center, emphasize the inherent limitations of pelvic lymphadenectomy. They highlight the prolonged operative duration and increased risks of vascular and neural injury, lymphedema, lymphocyst, venous thromboembolism, and surgery-related death associated with this procedure. The study's findings suggest that sentinel-lymph node biopsy alone may be a safer and more effective approach, particularly in reducing AEs.
This groundbreaking research opens up new possibilities for cervical cancer treatment, encouraging further investigation into the potential benefits of omitting lymphadenectomy. It invites discussions among medical professionals and patients alike, sparking a much-needed conversation about the role of lymphadenectomy in cervical cancer management.
